Alkermes

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Alkermes and other ETFs, options, and stocks.

About ALKS

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL.

CEO

Richard F. Pops

CEORichard F. Pops

Employees

2,100

Employees2,100

Headquarters

Dublin, Dublin

HeadquartersDublin, Dublin

Founded

2011

Founded2011

Employees

2,100

Employees2,100

ALKS Key Statistics

Market cap

4.04B

Market cap4.04B

Price-Earnings ratio

11.38

Price-Earnings ratio11.38

Dividend yield

—

Dividend yield—

Average volume

2.21M

Average volume2.21M

High today

$23.87

High today$23.87

Low today

$23.48

Low today$23.48

Open price

$23.65

Open price$23.65

Volume

2.15M

Volume2.15M

52 Week high

$33.17

52 Week high$33.17

52 Week low

$21.66

52 Week low$21.66

ALKS News

Yahoo Finance 3d

Alkermes to Report First Quarter Financial Results on May 1, 2024 - Yahoo Finance

DUBLIN, April 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wedne...

Yahoo Finance 3d

Alkermes Earnings Expected to Grow: What to Know Ahead of Q1 Release - Yahoo Finance

The market expects Alkermes (ALKS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024....

TipRanks 5d

Alkermes price target lowered to $23 from $25 at UBS

UBS lowered the firm’s price target on Alkermes to $23 from $25 and keeps a Sell rating on the shares. UBS believes Alkermes stock will likely continue to under...

Analyst ratings

54%

of 13 ratings

Buy

53.8%

Hold

38.5%

Sell

7.7%